The first of these compounds, tirzepatide—approved for both obesity and T2DM—acts as a dual agonist on the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.